Role of Gangliosides in Active Immunotherapy with Melanoma Vaccine

References

• von Leyden V. E., Blumenthal E. Vorlautige Mittheilungen uber einige Ergebnisse der Krebsforschung auf der 1. medizinischen Klinik. Dt. Med. Wschr. 1902; 28: 637–641
   Google Scholar
• Coca A. E., Dorrance G. M., Lebredo M. G. Vaccination in cancer: A report of the results of vaccination therapy as applied to seventy-nine cases of human cancer. Z. Immun. Exp. Ther. 1912; 13: 543–548
   Google Scholar
• Coca A. E., Gilman G. The specific treatment of carcinoma. Phil. J. Sci. Med. 1909; 4: 381–385
   Google Scholar
• Risley E. H. The Gilman-Coca vaccine emulsion treatment of cancer. Boston Med. Surg. J. 1911; 165: 784–788
   Google Scholar
• Vaughan J. W. Cancer vaccine and anti-cancer globulin as an aid in the surgical treatment of malignancy. JAMA. 1914; 63: 1258–1261
   Google Scholar
• Graham J. B., Graham R. M. Autologous vaccine in cancer patients. Surg. Gynec. Obstet. 1962; 109: 121–126
   Google Scholar
• Coley W. B. The treatment of inoperable sarcoma with the mixed toxins of erysipelas and bacillus prodigiosus. JA.MA. 1898; 31: 389–395
   Google Scholar
• Coley W. B. The mixed toxins of erysipelas and bacillus prodigiosus in the treatment of sarcoma. J.A.M.A. 1900; 34: 906–908
   Google Scholar
• De Pace N. G. Sulla scomparsa di un enorme cancro vegetante del collo del l'utero senza cura chirurgica. Ginecologia (Firenze) 1912; 9: 82–88
   Google Scholar
• Pack G. X. Note on the experimental use of rabies vaccine for melanomatosis. Arch. Dermatol. Syphilol. 1950; 62: 694–695
   Google Scholar
• Burdick K. H. Malignant melanoma treated with vaccinia injections. Arch. Dermatol. 1960; 82: 438–439
   Web of Science ®Google Scholar
• Finney J. W., Byers E. H., Wilson R. H. Studies in tumour auto-immunity. Cancer Res. 1960; 20: 351–356
   PubMedGoogle Scholar
• Hughes L. E., Kearney R., Tully M. A study in clinical cancer immunotherapy. Cancer 1970; 26: 269–272
   PubMedGoogle Scholar
• Cunningham T. J., Olson K. B., Laffin R., Horton J., Sullivan J. Treatment of advanced cancer with active immunization. Cancer 1969; 24: 932–936
   PubMed Web of Science ®Google Scholar
• Mathe G., Amiel J. L., Schwarzeberg L. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; I: 697–701
   Google Scholar
• Morton D. L., Eilber R. F., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surg. 1970; 68: 158–161
   PubMed Web of Science ®Google Scholar
• Cohen M. H., Jessup J. M., Felix E. L., Wesse J. L., Herberman R. B. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective study of intralesional bacillus Calmette-Guerin verus intralesional dinitrochlorobenzene. Cancer 1978; 41: 2456–2458
   PubMed Web of Science ®Google Scholar
• Garas J., Besbeas S., Papmatheakis J., Gropas G., Maragoudakis S., Katsenis A., Kiparissiadis P., Konstadakos P., Georgaka A. Attempt with immunotherapy to control metastatic skin nodules from breast cancer by BCG. Paniminerva Med. 1975; 17: 193–195
   PubMedGoogle Scholar
• Israel L., de Pierre A., Edelstein R. Effect of intranodual BCG in 22 melanoma patients. Proc. IVth Internatl. Symp. Locoregional Treatment of Tumors, TurinItaly, Sept., 19–211973. IUCC, 211
   Google Scholar
• Lieberman R., Wybran J., Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer 1975; 35: 756–760
   PubMed Web of Science ®Google Scholar
• Mastrangelo M. X., Sulit H. L., Prehn L. M., Bornstein R. S., Yarbo J. W., Prehn R. T. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 1976; 37: 684–690
   PubMedGoogle Scholar
• Nathanson L. Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother. Rep. 1972; 56: 659–662
   PubMedGoogle Scholar
• Nathanson L., Schoenfeld D., Regelson W., Colsky J., Mittelman A. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer 1979; 46: 1640–1645
   Google Scholar
• Pinsky C. M., Hirshaut Y., Oettgen H. F. Treatment of malignant melanoma by intratumoral injection of BCG. Natl. Cancer Inst. Monogr. 1973; 39: 225–235
   PubMedGoogle Scholar
• Bornstein R. S., Mastrangelo M. J., Sulit H. Immunotherapy of melanoma with intralesional BCG. Natl. Cancer Inst. Monogr. 1973; 39: 213–219
   PubMedGoogle Scholar
• Morton D. L., Hunt K. K., Bauer R. L., Lee J. D. Immunotherapy by active immunization of the host using mono-specific agents. Clinical Applications Using Intralesional Therapy, S. A. Rosenberg. J.B. Lippincott, Philadelphia 1991; 627–642
   Google Scholar
• Ribi E., Milner K. C., Granger-Kelley M. T., Yamamoto K., Brehner W., Parker R., Smith R. E., Strain S. M. Immunotherapy with non-viable microbial components. Ann. N. Y. Acad. Sci. 1976; 277: 227–238
   Google Scholar
• Vosika G. J. Clinical immunotherapy trials of bacterial components derived from mycobacteria and nocardia. J. Biol. Res. Mod. 1983; 2: 321–329
   PubMedGoogle Scholar
• Vosika G. J., Schmidtke J. R., Goldman A., Parker R., Gray G. R. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3). Cancer 1979; 44: 495–502
   PubMed Web of Science ®Google Scholar
• Kageshita T., Nakamura T., Yamada M., Kuriya N., Arao X., Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991; 51: 1726–1732
   PubMed Web of Science ®Google Scholar
• Stade B. G., Lehmann J., Riethmoller G., Johnson J. P. Markers for melanoma progression. J. Cancer Res. Clin. Oncol. 1990; 166: 784, (Suppl.)
   Google Scholar
• Ravindranath M. H., Irie R. E. Gangliosides as antigens of human melanoma. Malignant Melanoma: Biology, Diagnosis and Therapy, L. Nathanson. Kluwer Academic Publishers, Boston 1988; 14–17
   Google Scholar
• Nudelman E., Hakomori S., Kannagi R., Levery S., Yeh M. -Y., Hellstrom K. E., Hellstrom I. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody 4.2. J. Biol. Chem. 1982; 257: 12752–12756
   PubMed Web of Science ®Google Scholar
• Young W. W., Jr., Durdik J. M., Urdal D., Hakomori S., Henny C. S. Glycolipid expression in lymphoma cell variants: Chemical quantity, immunologic reactivity, and correlations with susceptibility to NK cells. J. Immunol. 1981; 126: 1–6
   PubMedGoogle Scholar
• Nakakuma H., Arai M., Kawaguchi X., Horikawa K., Hidaka M., Sakamoto K., Iwamori M., Nagai Y., Takatsuki K. Monoclonal antibodies to galactosylceramide: Discrimination of structural differences in the ceramide moiety. FEBS Lett. 1989; 258: 230–232
   PubMedGoogle Scholar
• Hakomori S. General concept of tumor-associated carbohydrate antigens: Their chemical, physical and enzymatic basis. Gangliosides and Cancer, H. E. Oettgen. VCH Publishers, New York 1989; 57–68
   Google Scholar
• Welt S., Carswell E. A., Vogel C. W., Oettgen H. E., Old L. J. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin. Immunol. Immunopathol. 1987; 45: 214–220
   PubMedGoogle Scholar
• Nores G. A., Dohi X., Taniguchi M., Hakomori S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen. J. Immunol. 1987; 139: 3171–3176
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Miraldi E. D. Iodine 132 labelled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma. Prog. Clin. Biol. Res. 1988; 27: 595–601
   Google Scholar
• Cheung N. K., Lazarus H., Miraldi E. D., Abramowsky C. R., Kallick S., Saarinen U. M., Spitzer T., Strandjord S. E., Coccia P. E., Berger N. A. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 1987; 5: 1430
   PubMed Web of Science ®Google Scholar
• Carubia J. M., Yu R. K., Macala L. J., Kirkwood J. M., Varga J. M. Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun. 1984; 120: 500–505
   PubMed Web of Science ®Google Scholar
• Cahan L. D., Irie R. E., Singh R., Cassidenti A., Paulson J. C. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. USA 1982; 79: 7629–7633
   PubMed Web of Science ®Google Scholar
• Tai T., Paulson J. C., Cahan L. D., Irie R. F. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc. Natl. Acad. Sci. USA 1983; 80: 5392–5396
   PubMed Web of Science ®Google Scholar
• Tsuchida T., Saxton R. E., Morton D. L., Irie R. E. Gangliosides of human melanoma. J. Natl. Cancer Inst. 1987; 78: 45–54
   PubMed Web of Science ®Google Scholar
• Tsuchida T., Ravindranath M. H., Saxton R. E., Irie R. E. Gangliosides of human melanoma: Altered expression in vivo and in vitro. Cancer Res. 1987; 47: 1278
   PubMed Web of Science ®Google Scholar
• Tsuchida T., Saxton R. E., Irie R. E. Gangliosides of human melanoma: GM2 and tumorigenicity. J. Natl. Cancer Inst. 1987; 78: 55–60
   PubMed Web of Science ®Google Scholar
• Ravindranath M. H., Paulson J. C., Irie R. F. Human melanoma associated antigen o-acetyl-ganglioside GD is recognized by cancer antennarius lectin. J. Biol. Chem. 1985; 260: 8838–8845
   PubMedGoogle Scholar
• Ravindranath M. H., Tsuchida T., Irie R. F. Diversity of ganglioside expression in human melanoma. Gangliosides and Cancer, H. E. Oettgen. VCH Publishers, New York 1989; 79–92
   Google Scholar
• Irie R. E., Ravindranath M. H. Gangliosides as targets for monoclonal antibody therapy of cancer. Therapeutic Monoclonal Antibodies, C. A. K. Borrebaeck, J. W. Larrick. Stockton Press, New York 1990; 75–94
   Google Scholar
• Schroder C., Nohle U., Shukla A. K., Schauer R. Improved methods for the isolation and structural analysis of trace amounts of new sialic acids identification of N-glycolylneuraminic acid in man. Glycoconjugates, Proc. 12th Intl. Symp., France, 1987, 162–163
   Google Scholar
• Kawai X., Kato A., Higashi H., Kato S., Naiki M. Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor associated sialic acid by gas chromatography mass spectrometry. Cancer Res. 1991; 51: 1242–1247
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y., Higashi H., Kato S., Taniguchi M., Matsumoto M. Occurrence of tumor associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas. Jpn. J. Cancer Res. 1987; 78: 614–620
   PubMedGoogle Scholar
• Cheresh D. A., Varki A. E., Varki N. M., Stallcup W. B., Levine J., Reisfeld R. A. A monoclonal antibody recognizes an O-acetyl sialic acid in a human melanoma-associated ganglioside. J. Biol. Chem. 1984; 259: 7453–7459
   PubMed Web of Science ®Google Scholar
• Thurin J., Herlyn M., Hindsgaul O., Stromberg N., Karlsson K. -A., Elder D., Steplewski Z., Koprowski H. Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl GD3. J. Biol. Chem. 1985; 260: 14556–14563
   PubMedGoogle Scholar
• Berd D., Herlyn M., Koprowski H., Mastrongelo M. J. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res. 1989; 49: 6840
   PubMed Web of Science ®Google Scholar
• Kath R., Rodeck U., Menssen H. D., Mancianti M. -L., Linnenbach A. J., Elder D. E., Herlyn M. Tumor progression in the human melanocytic system. Anticancer Res. 1989; 9: 865–872
   PubMed Web of Science ®Google Scholar
• Kanda S., Cochran A. J., Lee W. R., Morton D. L., Irie R. F. Unique ganglioside profile of uveal melanoma. Proc. Amer. Assoc. Cancer Res. 1991; 32: 257
   Google Scholar
• Nowell P. C. Mechanisms of tumor progression. Cancer Res. 1986; 46: 2203
   PubMed Web of Science ®Google Scholar
• Heppner G. H. Tumor heterogeneity. Cancer Res. 1984; 44: 2259
   PubMed Web of Science ®Google Scholar
• Herlyn M., Thurin J., Balaban G., Bennicelli J. L., Herlyn D., Elder D. E., Bondi E., Guerry D., Nowell R., Clark W. H., Koprowski H. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985; 45: 5670
   PubMed Web of Science ®Google Scholar
• Ravindranath M. H., Tsuchida T., Morton D. L., Irie R. E. Gangliosides GM3:GD3 ratio as an index for management of melanoma. Cancer 1991; 67: 1
   PubMedGoogle Scholar
• Parmiter A. H., Nowell P. C. The cytogenetics of human malignant melanoma and premalignant lesions. Malignant Melanoma: Biology, Diagnosis and Therapy, L. Nathanson. Kluwer Academic Publishers, Boston 1988; 47–62
   Google Scholar
• Herlyn M., Rodeck U., Koprowski H. Shedding of human tumor associated antigens in vitro and in vivo. Adv. Cancer Res. 1987; 49: 189
   PubMedGoogle Scholar
• Herlyn M., Guerry D., Koprowski H. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells and primary and metastatic melanoma. J. Immunol. 1985; 134: 4226
   PubMedGoogle Scholar
• Portoukalian J. Immunoregulatory activity of gangliosides shed by melanoma tumors. Gangliosides and Cancer, H. E. Oettgen. VCH Publishers, New York, 207–216
   Google Scholar
• Tsuchida T., Otsuka H., Niimura M., Inoue Y., Kukita A., Hashimoto Y., Seyama Y., Yamakawa T. Biochemical study on gangliosides neurofibromas and neurofibro-sarcomas of Recklinghausen's disease. J. Dermatol. 1984; 11: 129–136
   PubMedGoogle Scholar
• Portoukalian J., Zwinglestein G., Abdul-Malek N., Dore J. F. Alteration of gangliosides in plasma and red cells of human bearing melanoma tumors. Biochem. Biophys. Res. Commun. 1978; 85: 916
   PubMedGoogle Scholar
• Hakansson L., Fredman P., Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J. Biochem. 1985; 98: 843
   PubMedGoogle Scholar
• Sela B. -A., Iliopouios D., Guerry D., Herlyn D., Koprowski H. Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thin layer chromatography and immunostaining. J. Natl. Cancer Inst. 1989; 81: 1489–1492
   PubMedGoogle Scholar
• Ladisch S., Gillard B., Wong C., Ulshm L. Shedding and immunosuppressive activity of YAC lymphoma cell gangliosides. Cancer Res. 1983; 43: 3803–3813
   Google Scholar
• Ladisch S., Ulsh L., Gillard B., Wong C. Modulation of the immune response by gangliosides: inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 1984; 74: 2074–2081
   PubMedGoogle Scholar
• Ladisch S., Becker H., Ulsh L. Carbohydrate structure and immunosuppression by human gangliosides. Proc. Amer. Assoc. Cancer Res. 1991; 32: 226
   Google Scholar
• Miller H. C., Esselman W. J. Modulation of immune response by antigen reactive lymphocytes after cultivation with gangliosides. J. Immunol. 1975; 115: 839–843
   PubMedGoogle Scholar
• Lengle E. E., Krishnaraj R., Kemp R. G. Inhibition of the lectin-induced mitogenic response of thymocytes by glycolipids. Cancer Res. 1979; 39: 817–822
   PubMedGoogle Scholar
• Ryan J. L., Shinitzky M. Possible role for glycosphingolipids in the control of immune responses. Eur. J. Immun. 1979; 9: 171–175
   PubMedGoogle Scholar
• Whisler R. L., Yates A. J. Regulation of lymphocyte responses by human gangliosides. J. Immunol. 1980; 125: 2106–2111
   PubMed Web of Science ®Google Scholar
• Gonwa T. A., Westrick M. A., Macher B. A. Inhibition of mitogen- and antigen-induced lymphocyte activation by human leukemia cell gangliosides. Cancer Res. 1984; 44: 3467–3470
   PubMed Web of Science ®Google Scholar
• Prokazova N. V., Dyatlovitskaya E. V., Bergelson L. D. Sialylated lactosylceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions. Eur. J. Biochem. 1988; 171: 1–6
   PubMedGoogle Scholar
• Merritt W. D., Bailey M., Pluznik D. H. Inhibition of interleukin-2 dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol. 1984; 89: 1–10
   PubMed Web of Science ®Google Scholar
• Offner H., Thieme T., Vandenbark A. A. Gangliosides induce selective modulation of CD4 from helper T lymphocytes. J. Immunol. 1987; 139: 3295–3305
   PubMed Web of Science ®Google Scholar
• Kawaguchi T., Nakakuma H., Kagimoto T., Shirono K., Horikawa K., Hidaka M., Iwamori M., Nagai Y., Takatsuki K. Characteristic mode of action of gangliosides in selective modulation of CD4 on human T lymphocytes. Biochem. Biophys. Res. Commun. 1989; 158: 1050–1059
   PubMedGoogle Scholar
• Morrison W. J., Offner H., Vandenbark A. A. Specific ganglioside binding to receptor sites on T lymphocytes that couple to ganglioside-induced decrease of CD4 expression. Life Sci. 1989; 45: 1219–1226
   PubMedGoogle Scholar
• Agarwal M. K., Neter E. Effect of selected lipids and surfactants on immunogenicity of several bacterial antigens. J. Immunol. 1971; 107: 1448–1456
   PubMedGoogle Scholar
• Esselman W. J., Miller H. C. Modulation of B cell responses by glycolipid released from antigen-stimulated T cells. J. Immunol. 1977; 19: 1994–2000
   Google Scholar
• Hoon D. S. B., Trie R. E., Cochran A. J. Gangliosides from melanoma immunomodulate response of T-cells to interleukin-2. Cell Immunol. 1111; 1988
   Google Scholar
• Do I., Hoon D. S. B., Suzuki Y., Saxton R. E., Golub S. H., Irie R. F. Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int. J. Cancer 1987; 40: 12–17
   PubMedGoogle Scholar
• Ando I., Hoon D. B., Pattengale P. K., Golub S. H., Irie R. F. Ganglioside GM2 as a target structure recognized by human natural killer cells. J. Clin. Lab. Anal. 1987; 1: 209–213
   Google Scholar
• Fukuta S., Werkmeister J. A., Burns G. E., Ginsburg V., Magnani J. L. Monoclonal antibody Leo Mel 3, which inhibits killing of human melanoma cells by anomalous killer cells, binds to a sugar sequence in GD2 (II 3 (NeuAc)2-GgOse3Cer) and several other gangliosides. J. Biol. Chem. 1987; 262: 4800–4803
   PubMedGoogle Scholar
• Ladisch S., Wu Z. L., Feig S., Ulsh L., Schwartz E., Floutsis G., Wiley E., Lenarsky C., Seeger R. Shedding of GD2 gangliosides by human neuroblastoma. Int. J. Cancer 1987; 39: 73–76
   PubMed Web of Science ®Google Scholar
• Hellstrom I., Brankovan V., Hellstrom K. E. Strong anti-tumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc. Natl. Acad. Sci. USA 1985; 82: 1499–1502
   PubMedGoogle Scholar
• Cheresh D. A., Honsik C. I., Staffileno L. K., Jung G., Reisfeld R. A. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc. Natl. Acad. Sci. USA 1985; 82: 5155–5159
   PubMed Web of Science ®Google Scholar
• Honsik C. J., Jung G., Reisfeld R. A. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc. Natl. Acad. Sci. USA 1986; 83: 7893–7897
   PubMed Web of Science ®Google Scholar
• Harel W., Shau H., Hadley C. G., Morgan A. C., Reisfeld R. A., Cheresh D. A., Mitchell M. S. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res. 1990; 50: 6311–6315
   PubMedGoogle Scholar
• Iliopoulos D., Ernst C., Steplewski Z., Jambrosic J. A., Rodeck U., Herlyn M., Clark W. H., Koprowski H., Herlyn D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to GD2/GD3 gangliosides. J. Natl. Cancer Inst. 1989; 81: 440–444
   PubMedGoogle Scholar
• Livingston R. O., Natoli E. J., Calves M. J., Stockert E., Oettgen H. F., Old L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA 1987; 84: 2911–2915
   PubMed Web of Science ®Google Scholar
• Katano M., Jien M., Irie R. F. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft. Eur. J. Cancer Clin. Oncol. 1984; 20: 1053–1059
   PubMedGoogle Scholar
• Irie R. E., Morton D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. USA 1986; 83: 8694–8698
   PubMed Web of Science ®Google Scholar
• Irie R. E., Matsuki T., Morton D. L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989; 1: 786–787
   PubMed Web of Science ®Google Scholar
• Dippold W., Knuth A., Meyer zum Buschenfeld K. -H. Inflammatory response at the tumor site after systemic application of monoclonal anti-GD3-ganglioside antibody to patients with malignant melanoma. Am. Assoc. Cancer Res. 1984; 978: 247
   Google Scholar
• Houghton A. N., Mintzer D., Cordon-Cardo C., Welt S., Fliegel B., Vadhan S., Carswell E., Melamed M. R., Oettgen H. E., Old L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 1985; 84: 1242–1246
   Google Scholar
• Bajorin D., Chapman P., Kunicka J., Cordon-Cardo C., Welt K., Mertelsmann R., Melamed M., Oettgen H. E., Old L. J., Houghton A. H. Phase I trial of a combination of R24 mouse monoclonal antibody and recombinant interleukin-2 in patients with melanoma. Amer. Assoc. Cancer Res. 1987; 827: 210
   Google Scholar
• Cheung N. V., Lazarus H., Miraldi E. D., Abramowsky C. R., Kallick S., Saarinen U. M., Spitzer T., Strandjord S. E., Coccia R. E., Berger N. A. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastma and malignant melanoma. J. Clin. Oncol. 1987; 5: 1430–1440
   PubMed Web of Science ®Google Scholar
• Lichitin A. E., Guerry D., Elder D. E., Hamilton R., LaRossa D., Herlyn D., Iliopoulous D., Thurin J., Steplewski Z. A phase I study of monoclonal antibody therapy in disseminated melanoma. Proc. 8th Internatl. Pigment Cell Conf., Tucson, Arizona, 1986
   Google Scholar
• Goodman G. E., Hellstrom I., Hummel D., Brodzinsky L., Yeh M. Y., Hellstrom K. E. Phase I trial of monoclonal antibody MG-21 directed against a melanoma associated GD3 ganglioside antigen. Proc. Amer. Soc. Clin. Oncol. 1987; 6: A823
   Google Scholar
• Vadhan-Raj S., Cordon-Cardo C., Carswell E., Mintzer D., Dantis L., Duteau C., Templeton M. A., Oettgen H. E., Old L. J., Houghton A. N. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma; induction of inflammatory responses at tumor sites. J. Clin. Oncol. 1988; 6: 1636–1648
   PubMed Web of Science ®Google Scholar
• Yamaguchi H., Furukawa K., Fortunato S. R., Livingston E. O., Lloyd K. O., Oettgen H. R., Old L. J. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1987; 84: 2416–2420
   PubMed Web of Science ®Google Scholar
• Ravindranath M. H., Morton D. L., Irie R. E. An epitope common to gangliosides 0-AcGD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 1989; 49: 3891–3897
   PubMed Web of Science ®Google Scholar
• Pukel C. S., Lloyd K. O., Travassos L. R., Dippold W. G., Oettgen H. E., Old L. J. GD3, a prominent ganglioside of human melanoma: Detection and characterization of mouse monoclonal antibody. J. Exp. Med. 1982; 155: 1133–1147
   PubMed Web of Science ®Google Scholar
• Tai X., Kawashima I., Furukawa K., Lloyd K. O. Monoclonal antibody R24 distinguishes between different N-acetyl and N-glycolyl neuraminic acid derivatives of ganglioside GD3. Arch. Biochem. Biophys. 1988; 260: 51–55
   PubMedGoogle Scholar
• Ritter G., Boosfeld E., Markstein E., Yu R. K., Ren S., Stallcup W. B., Oettgen H. E., Old L. J., Livingston E. O. Biochemical and serological characteristics of natural 9-O-Acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res. 1990; 50: 1403–1410
   PubMed Web of Science ®Google Scholar
• Brodin T., Hellstrom I., Hellstrom K. E., Karlsson K. -A., Sjogren H. -O., Stromberg N., Thurin J. Mouse monoclonal antibodies with specificity for the melanoma-associated ganglioside disiallylactosyl-ceramide (GD3) also react with the structural analoque disialylparagloboside. Biochem. Biophys. Acta 1985; 837: 349–353
   PubMedGoogle Scholar
• Takamizawa K., Iwamori M., Mutai M., Nagai Y. Selective changes in gangliosides of human milk during lactation: a molecular indicator for the period of lactation. Biochem. Biophys. Acta 1986; 879: 73–77
   PubMed Web of Science ®Google Scholar
• Holm M., Mansson J. E., Vanier M. T., Svennerholm L. Gangliosides of human, bovine and rabbit retina. Biochem. Biophys. Acta 1972; 280: 356–364
   PubMedGoogle Scholar
• Berra B. M., Riboni L., De Gasperi R., Gaini S. M., Ragnotti G. Modifications of ganglioside patterns in human meningiomas. J. Neurochem. 1983; 40: 777–782
   PubMed Web of Science ®Google Scholar
• Sunder-Plassman M., Bernheimer H. Ganglioside in meningiomen and heinhauten. Acta Neuropathol. (Berl.) 1974; 27: 289–294
   PubMedGoogle Scholar
• Etienne-Decerf J., Gosselin-Rey C., Gosselin L., Winand R. Effects of thyrotropin and thyroid stimulating immunoglobins on gangliosides labeling of human thymus cultured pathological cells. J. Endocrinol. Invest. 1986; 9: 57–63
   PubMedGoogle Scholar
• Bouchon B., Portoukalian J., Bornet H. Major gangliosides in normal and pathological human thyroids. Biochem. Int. 1985; 10: 531–538
   PubMedGoogle Scholar
• Prokazova N. V., Orekhov A. N., Mukin D. N., Mikhailenko I. A., Kogter L. S., Sadovskaya V. L., Golovanova N. K., Bergelson L. D. The gangliosides of adult human aorta: intima, media, and plaque. Eur. J. Biochem. 1987; 167: 349–352
   PubMedGoogle Scholar
• Hakomori B., Nudelmel E., Levery S. B., Patterson C. M. Human cancer-associated gangliosides defined by a monoclonal antibody (IB9) directed to sialosyl a2–6 galactosyl residue: a preliminary note. Biochem. Biophys. Res. Commun. 1983; 113: 791–798
   PubMedGoogle Scholar
• Rauvala H. Gangliosides of human kidney. J. Biol. Chem. 1976; 251: 7517–7520
   PubMed Web of Science ®Google Scholar
• Takahashi K., Ono K., Hirabayashi Y., Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J. Immunol. 1988; 140: 3244–3248
   PubMed Web of Science ®Google Scholar
• Livingston P. O., Ritter G., Oettgen H. E., Old L. J. Immunization of melanoma patients with purified gangliosides. Gangliosides and Cancer, H. F. Oettgen. VCH Publishers, New York 1989; 293–300
   Google Scholar
• Livingston P. O., Natoli E. J., Jr., Calves J., Gnecco C., Wong G. Y., Stockert E., Old L. J., Oettgen H. F. Immunization of melanoma patients with the ganglioside GM2. Proc. ASCO 1987; 6: 209
   Google Scholar
• Tai T., Cahan L. D., Tsuchida T., Saxton R. E., Irie R. E., Morton D. L. Immunogenicity of melanoma associated gangliosides in cancer patients. Int. J. Cancer 1985; 35: 607–612
   PubMed Web of Science ®Google Scholar
• Morton D. L., Hoon D. S. B., Gupta R. G., Nizze A. J., Famatiga E., Foshag L. J., Furutani S., Irie R. E. Treatment of malignant melanoma by active specific immunotherapy in combination with biological response modifiers. New Horizons of Tumor Immunotherapy, M. Torisu, T. Yoshida. Elsevier Sci Publ. B.V., FukuokaJapan 1989; 665–683
   Google Scholar
• Welt K., Miller G., Chapman P. B., Yuasa H., Natoli E., Kunicka J. E., Cordon-Cardo C., Buhrer C., Old L. J., Houghton A. N. Stimulation of T-lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J. Immunol. 1987; 139: 1763–1771
   PubMedGoogle Scholar
• Siegler H. E., Wallack M. K., Vervaert C. E., Bash J. A., Roberson K. M., Stuhlmiller G. M. Melanoma patient antibody response to melanoma tumor-associated antigens defined by murine monoclonal antibodies. J. Biol. Resp. Mod. 1989; 8: 37–52
   PubMedGoogle Scholar